

Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients

Nicholas Brennan¹, Mohammad H Dehabadi², Sandhya Nair³, Ana Quartilho⁴, Catey Bunce⁴, Ian Reekie³, Raal Obikpo³

¹Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK

²London North West Healthcare NHS Trust, London HA1 3UJ, UK

³North Middlesex University Hospital NHS Trust, London N18 1QX, UK

⁴NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London EC1V 2PD, UK

Correspondence to: Ian Reekie. North Middlesex University Hospital, Sterling Way, London N18 1QX, UK. ian.reekie@cantab.net

Received: 2016-10-27 Accepted: 2017-02-13

Abstract

• **AIM:** To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP) on current therapy.

• **METHODS:** Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired *t*-test at the 5% significance level.

• **RESULTS:** There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment ($P < 0.001$). Subgroup analysis also demonstrated a statistically significant mean reduction in IOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy ($P < 0.001$).

• **CONCLUSION:** This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.

• **KEYWORDS:** glaucoma; ocular hypertension; bimatoprost; latanoprost

DOI:10.18240/ijo.2017.08.11

Citation: Brennan N, Dehabadi MH, Nair S, Quartilho A, Bunce C, Reekie I, Obikpo R. Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. *Int J Ophthalmol* 2017;10(8):1251-1254

INTRODUCTION

Glaucoma is a complex neurodegenerative condition estimated to affect 64.3 million people worldwide in 2013, a number that is predicted to rise to 111.8 million by 2040^[1]. The only modifiable risk factor in the treatment of glaucoma to date is the reduction of intraocular pressure (IOP)^[2]. Prostaglandin analogues (PGAs; bimatoprost, latanoprost, Travaprost) are commonly the first line agents used to lower IOP in primary open angle glaucoma (POAG), and ocular hypertension (OHT)^[3]. Although the precise mechanism of action of these drugs is not known, it is widely accepted that they act to increase aqueous outflow *via* two pathways; uveoscleral outflow increase by extracellular matrix remodeling^[4], and trabecular outflow increase^[5].

Meta-analyses have shown bimatoprost 0.03% to be equivalent in its IOP lowering efficacy when compared to Travaprost, or Latanoprost^[6]. In recent years however, there has been a small, but growing body of Allergan sponsored literature^[7-14], as well as independent studies^[15-18] supporting the use of Bimatoprost in patients with OHT, normal tension glaucoma (NTG), and POAG who are deemed 'non-responders' on their current treatment. The largest independent study currently in the literature consisted of 46 patients with POAG or OHT and found no significant benefit from a switch to bimatoprost monotherapy^[17].

We present an independent observational study of glaucoma and OHT patients with inadequate IOP control on current therapy that were switched to bimatoprost 0.03% monotherapy.

SUBJECTS AND METHODS

Consecutive 'non-responder' patients with IOPs above their target IOP on current treatment were prospectively identified by the lead glaucoma consultant between July 2011 and Jan 2015. These patients were switched from their current IOP lowering agent to bimatoprost 0.03% monotherapy only.

Bimatoprost for non-responsive glaucoma and ocular hypertension

Data collection was carried out retrospectively, through case note review and clinical electronic data base searches. Information on patient demographics, diagnosis, pre-switch treatment, pre-switch IOP, IOP at all available post-switch clinics, as well as any adverse events were recorded.

To be included patients required a minimum of one follow up visit; documentation of pre- and post-switch IOP recordings, pre-switch therapy and documentation of any adverse events. Any participants with active ocular disease except glaucoma or receiving ocular treatment which may affect the IOP were excluded. The structure of the study is shown in Figure 1.

This study was approved by the institutional review board and followed the regulations of the Personal Information Protection and Electronic Documents Act and the Good Clinical Practice Guidelines of the Declaration of Helsinki.

Change in IOP post-pre switch was analyzed using a 2-sided Student's paired *t*-test at the 5% significance level for left eye and then for right eye (to assess consistency).

RESULTS

Adequate follow up data for analysis was obtained for a total of 59 consecutive patients following the clinical records search. Patient demographics are detailed in Table 1. The majority of patients had OHT as their working diagnosis, with over half on monotherapy with latanoprost before being switched to bimatoprost. The mean pre-switch IOP for all study patients regardless of diagnosis was 23.4 mm Hg.

Intraocular Pressure Effects of Bimatoprost Monotherapy at First Follow up The average time between switch to bimatoprost and the first follow up appointment was 104±44d. The mean reduction in IOP from pre-switch IOP at this time point for right eyes was: -4.24 mm Hg; 95%CI (-5.49 to -2.1); $P<0.001$ ($n=58$), and the mean reduction in IOP at this time point for left eyes was: -4.42 mm Hg; 95%CI (-5.4 to -2.45); $P<0.001$ ($n=59$).

At the first follow up visit, 16 (27%) of patients were deemed to have unsatisfactory IOP, and were either switched to other therapy, or listed for selective laser trabeculoplasty. The remaining 33 (55.9%) patients remained on bimatoprost monotherapy, as their IOP was deemed satisfactory.

Subgroup Analysis

Ocular hypertension patients switched to bimatoprost The mean reduction in IOP for OHT patients at first follow up appointment for right eyes ($n=47$) was -4.11 mm Hg; 95%CI (-5.62 to -2.59); $P<0.001$. The mean reduction in IOP for OHT patients at first follow up appointment for left eyes ($n=48$) was -4.52 mm Hg; 95%CI (-5.67 to -3.37); $P<0.001$.

Patients switched from latanoprost monotherapy to bimatoprost monotherapy For patients with any diagnosis, switched from latanoprost monotherapy to bimatoprost monotherapy ($n=37$), the mean reduction in IOP at first follow up appointment was -5.27 mm Hg; 95%CI (-6.87 to -3.67);




Figure 1 Study structure.

Table 1 Baseline characteristics of study patients n (%)

Characteristics	Values
Age (a)	
Mean (range)	64 (42-88)
Sex	
M	31 (53)
F	28 (47)
Race	
Caucasian	23 (39)
Black	24 (41)
Asian	12 (20)
Diagnosis	
OHT	43 (73)
POAG	6 (10)
NTG	4 (7)
PAC-OHT	5 (8)
PACG	1 (2)
IOP-lowering Rx	
Latanoprost	39 (66)
Travoprost	11 (19)
Travoprost/Timolol combination drop	3 (5)
Latanoprost+Dorzolamide/Timolol combination drop	2 (3)
Dorzolamide+Travoprost/Timolol combination drop	2 (3)
Brinzolamide+Bimatoprost/Timolol combination drop	1 (2)
Latanoprost/Timolol combination drop	1 (2)
Mean Pre-switch IOP (mm Hg)	
Right eye	23.2±4.4
Left eye	23.3±3.7

$P<0.001$ for right eyes, and -5.27 mm Hg; 95%CI (-6.56 to -3.98); $P<0.001$ for left eyes.

Intraocular Pressure Effects of Bimatoprost Monotherapy at Second Follow up Second follow up appointment data were available for 30 patients. The average time from switch to bimatoprost to second follow up appointment was 320±109d. The mean reduction in IOP from pre-switch IOP at this time point for right eyes was: -6.31 mm Hg; 95%CI (-8.58 to -4.04); $P<0.001$ ($n=30$), and the mean reduction in IOP at this time point for left eyes was: -7.95 mm Hg; 95%CI (-8.75 to -5.25); $P<0.001$ ($n=30$).

Table 2 Mean IOP at each follow-up visit

IOP	Pre-switch (n=59)	1 st follow up (104±44d; n=59)	2 nd follow up (320±109d; n=30)	3 rd follow up (490±145d; n=18)	4 th follow up (708±160d; n=8)
Mean IOP (mm Hg)	23.2	18.9	16.6	15.5	16.8
Range	14-34	10-27	10-37	8-20	13-24

The summary of mean IOP at each follow up visit can be found in Table 2.

Adverse Events Of all patients in the study, four adverse events were recorded; three patients reported increased conjunctival hyperaemia post-switch from Travaprost, and treatment was discontinued. Another patient reported frequent headaches associated with the switch to bimatoprost, but in this case, these side effects were deemed minor, and the patient continued on bimatoprost monotherapy.

DISCUSSION

We present the largest independent data set published to date following the progress of patients switched to bimatoprost 0.03% monotherapy due to inadequate response to previous therapy. Our findings suggest that for some patients with glaucoma who fail to respond adequately to mono, dual, and triple medical therapy, bimatoprost 0.03% appears to offer statistically, and clinically significant additional IOP reduction. For over 55.9% of non-responder patients a switch to bimatoprost monotherapy provided adequate IOP response at first follow up. As demonstrated by our long-term follow up data, the initial IOP reductions seen appear to be sustained, or even modestly improved by 10mo.

Our subgroups analyses show that there is a statistically significant reduction in IOP in OHT patients who are switched from any current treatment to bimatoprost monotherapy. This is important, as the aim with OHT patients should always be to achieve adequate control using medical monotherapy, and bimatoprost appears to allow this to occur in patients not responding to other therapy.

The second subgroup analysis compared latanoprost monotherapy to bimatoprost monotherapy in patients with a mixture of diagnoses; again, a statistically significant reduction in IOP was seen upon switch, suggesting that non-responders to latanoprost monotherapy should always have a trial switch to bimatoprost monotherapy before moving onto dual medical therapy, or selective laser trabeculoplasty.

To date, latanoprost remains the most commonly prescribed first line PGA in patients with OHT and POAG, and this is confirmed by our baseline patient demographics. Incidence of latanoprost nonresponse has been reported to be as high as 28.1% in the Japanese population^[19]. A mixture of industry sponsored^[9-10,13], and independent^[15-16] short- and long-term studies have demonstrated an additional IOP lowering effect of bimatoprost when compared to latanoprost.

A number of reasons have been put forward for bimatoprost's additional IOP lowering efficacy when compared with other PGAs; PGAs such as latanoprost are pro-drugs that require de-esterification to yield an active drug. It has been speculated that poor de-esterification of latanoprost could explain the cohort of latanoprost non-responders^[15]. PGAs act primarily *via* prostaglandin F_{2α} prostanoid receptors^[20], whereas there is *in vitro*, and *ex vivo* evidence based on a human anterior segment model that bimatoprost acts on a distinct prostamide receptor in the trabecular meshwork, increasing outflow by approximately 40%^[21].

Results from our small observational study support switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy. The benefits of this approach include sustained IOP reduction on monotherapy, avoidance of increased cost and side effects of poly-pharmacy, and improved patient compliance due to simplicity of regime.

While the exact mechanisms by which Bimatoprost produces its additional IOP lowering effects on non-responders remains to be elucidated, there is a growing body of evidence that this prostamide appears to exhibit additional IOP lowering efficacy when compared to other PGAs.

Weaknesses of this study include a relatively small patient cohort of 59, and non-blindness of examiners to the patient's treatment. It is also noted that patient compliance to a single medication regimen may be better than to a multi-medication regimen.

ACKNOWLEDGEMENTS

Conflicts of Interest: Brennan N, None; Dehabadi MH, None; Nair S, None; Quartilho A, None; Bunce C, None; Reekie I, None; Obikpo R, None.

REFERENCES

- 1 Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* 2014; 121(11):2081-2090.
- 2 VanVeldhuisen PC, Ederer F, Gaasterland DE, Sullivan EK, Beck A, Prum BE, Cyrlin MN, Weiss H. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. *Am J Ophthalmol* 2000;130(4):429-440.
- 3 Li X, He F, Gabelt BT, Wang Y, Cai S, Cao, Fan N, Kaufman PL, Liu X. Effects of latanoprost and bimatoprost on the expression of molecules relevant to ocular inflow and outflow pathways. *PLoS One* 2016;11(3):e0151644.

Bimatoprost for non-responsive glaucoma and ocular hypertension

- 4 Richter M, Krauss AH, Woodward DF, Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. *Invest Ophthalmol Vis Sci* 2003;44(10):4419-4426.
- 5 Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. *Ophthalmology* 2008;115(5):790-795.
- 6 Kymes SM, Burk C, Feinman T, Williams JM, Hollander DA. Demonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacy. *Ther Clin Risk Manag* 2011;7:283-290.
- 7 Crichton AC, Nixon DR, Simonyi S, Bhogal M, Sigouin CS, Discepolo MJ, Hutnik CM, Baptiste DC, Yan DB. An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: The Canadian Lumigan[®]RC Early Analysis Review (CLEAR) trial. *Clin Ophthalmol* 2014;23(8):1031-1038.
- 8 Casson RJ, Liu L, Graham SL, Morgan WH, Grigg JR, Galanopoulos A, Crawford A, House PH. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study. *J Glaucoma* 2009;18(8):582-588.
- 9 Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. *Adv Ther* 2002;19(6):275-281.
- 10 Law SK, Song BJ, Fang E, Caprioli J. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. *Ophthalmology* 2005;112(12):2123-2130.
- 11 Bournias TE, Lee D, Gross R, Mattox C. Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension. *J Ocul Pharmacol Ther* 2003;19(3):193-203.
- 12 Pfennigsdorf S, Ramez O, vonKistowski G, Mäder B, Eschstruth P, Froböse M, Thelen U, Spraul C, Schnober D, Cooper H, Laube T. Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension. *Clin Ophthalmol* 2012;6:739-746.
- 13 Myers JS, Vold S, Zaman F, Williams JM, Hollander DA. Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials. *Clin Ophthalmol* 2014;27(8):643-652.
- 14 Konstas AG, Holló G, Irkec M, Tsironi S, Durukan I, Goldenfeld M, Melamed S. Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study. *Br J Ophthalmol* 2007;91(6):757-760.
- 15 Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. *Ophthalmology* 2003;110(3):609-614.
- 16 Sonty S, Donthamsetti V, Vangipuram G, Ahmad A. Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost. *J Ocul Pharmacol Ther* 2008;24(5):517-520.
- 17 Brittain CJ, Saxena R, Waldoek A. Prospective comparative switch study from timolol 0.5% and latanoprost 0.005% to bimatoprost 0.03%. *Adv Ther* 2006;23(1):68-73.
- 18 Sato S, Hirooka K, Baba T, Mizote M, Fujimura T, Tenkumo K, Ueda H, Shiraga F. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma. *J Ocul Pharmacol Ther* 2011;27(5):499-502.
- 19 Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. *Jpn J Ophthalmol* 2006;50(2):153-157.
- 20 Vielhauer GA, Fujino H, Regan JW. Cloning and localization of hFPS: a six-transmembrane mRNA splice variant of the human FP prostanoid receptor. *Arch Biochem Biophys* 2004;421(2):175-185.
- 21 Wan Z, Woodward DF, Cornell CL, Fliri HG, Martos JL, Pettit SN, Wang JW, Kharlamb AB, Wheeler LA, Garst ME, Landsverk KJ, Struble CS, Stamer WD. Bimatoprost, prostamide activity, and conventional drainage. *Invest Ophthalmol Vis Sci* 2007;48(9):4107-4115.